Cargando…

Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections

Urinary tract infections (UTIs) mainly caused by Uropathogenic Escherichia coli (UPEC), are common bacterial infections. Many individuals suffer from chronically recurring UTIs, sometimes requiring long-term prophylactic antibiotic regimens. The global emergence of multi-drug resistant uropathogens...

Descripción completa

Detalles Bibliográficos
Autores principales: Loubet, Paul, Ranfaing, Jérémy, Dinh, Aurélien, Dunyach-Remy, Catherine, Bernard, Louis, Bruyère, Franck, Lavigne, Jean-Philippe, Sotto, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350282/
https://www.ncbi.nlm.nih.gov/pubmed/32719668
http://dx.doi.org/10.3389/fmicb.2020.01509
_version_ 1783557234041552896
author Loubet, Paul
Ranfaing, Jérémy
Dinh, Aurélien
Dunyach-Remy, Catherine
Bernard, Louis
Bruyère, Franck
Lavigne, Jean-Philippe
Sotto, Albert
author_facet Loubet, Paul
Ranfaing, Jérémy
Dinh, Aurélien
Dunyach-Remy, Catherine
Bernard, Louis
Bruyère, Franck
Lavigne, Jean-Philippe
Sotto, Albert
author_sort Loubet, Paul
collection PubMed
description Urinary tract infections (UTIs) mainly caused by Uropathogenic Escherichia coli (UPEC), are common bacterial infections. Many individuals suffer from chronically recurring UTIs, sometimes requiring long-term prophylactic antibiotic regimens. The global emergence of multi-drug resistant uropathogens in the last decade underlines the need for alternative non-antibiotic therapeutic and preventative strategies against UTIs. The research on non-antibiotic therapeutic options in UTIs has focused on the following phases of the pathogenesis: colonization, adherence of pathogens to uroepithelial cell receptors and invasion. In this review, we discuss vaccines, small compounds, nutraceuticals, immunomodulating agents, probiotics and bacteriophages, highlighting the challenges each of these approaches face. Most of these treatments show interesting but only preliminary results. Lactobacillus-containing products and cranberry products in conjunction with propolis have shown the most robust results to date and appear to be the most promising new alternative to currently used antibiotics. Larger efficacy clinical trials as well as studies on the interplay between non-antibiotic therapies, uropathogens and the host immune system are warranted.
format Online
Article
Text
id pubmed-7350282
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73502822020-07-26 Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections Loubet, Paul Ranfaing, Jérémy Dinh, Aurélien Dunyach-Remy, Catherine Bernard, Louis Bruyère, Franck Lavigne, Jean-Philippe Sotto, Albert Front Microbiol Microbiology Urinary tract infections (UTIs) mainly caused by Uropathogenic Escherichia coli (UPEC), are common bacterial infections. Many individuals suffer from chronically recurring UTIs, sometimes requiring long-term prophylactic antibiotic regimens. The global emergence of multi-drug resistant uropathogens in the last decade underlines the need for alternative non-antibiotic therapeutic and preventative strategies against UTIs. The research on non-antibiotic therapeutic options in UTIs has focused on the following phases of the pathogenesis: colonization, adherence of pathogens to uroepithelial cell receptors and invasion. In this review, we discuss vaccines, small compounds, nutraceuticals, immunomodulating agents, probiotics and bacteriophages, highlighting the challenges each of these approaches face. Most of these treatments show interesting but only preliminary results. Lactobacillus-containing products and cranberry products in conjunction with propolis have shown the most robust results to date and appear to be the most promising new alternative to currently used antibiotics. Larger efficacy clinical trials as well as studies on the interplay between non-antibiotic therapies, uropathogens and the host immune system are warranted. Frontiers Media S.A. 2020-07-03 /pmc/articles/PMC7350282/ /pubmed/32719668 http://dx.doi.org/10.3389/fmicb.2020.01509 Text en Copyright © 2020 Loubet, Ranfaing, Dinh, Dunyach-Remy, Bernard, Bruyère, Lavigne and Sotto. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Loubet, Paul
Ranfaing, Jérémy
Dinh, Aurélien
Dunyach-Remy, Catherine
Bernard, Louis
Bruyère, Franck
Lavigne, Jean-Philippe
Sotto, Albert
Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections
title Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections
title_full Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections
title_fullStr Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections
title_full_unstemmed Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections
title_short Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections
title_sort alternative therapeutic options to antibiotics for the treatment of urinary tract infections
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350282/
https://www.ncbi.nlm.nih.gov/pubmed/32719668
http://dx.doi.org/10.3389/fmicb.2020.01509
work_keys_str_mv AT loubetpaul alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections
AT ranfaingjeremy alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections
AT dinhaurelien alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections
AT dunyachremycatherine alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections
AT bernardlouis alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections
AT bruyerefranck alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections
AT lavignejeanphilippe alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections
AT sottoalbert alternativetherapeuticoptionstoantibioticsforthetreatmentofurinarytractinfections